From VFC's News, Notes & Weekly Stock Watch at VFC's NEW Stock House.
APRI: Apricus Biosciences will be a stock worth watching into the coming week.
The dip back down to the five dollar mark last week makes APRI quite the buy, in my opinion, for a company with significant market moving potential and enough cash on hand to last until moving into the expected phase of cash-flow positive, which according to recent company reports, should take place by the end of this year.
Any pullback to the five dollar level should be eyeballed, and even moreso should the stock dip back down to below that mark.
This is a nice accumulation phase for APRI, and I think we'll see this one appreciate as time zooms in to cash flow positive and additional partnerships.
On the pipeline front, the company announced last week that the European Patent Office has granted a patent for MycoVA in the treatment of nail fungus. MycoVa is being geared up for Phase III trials and the European patent will provide Apricus with protection until 2024.
Keep an eye out for any unsuspecting dips, because Apricus is gearing up for the long term.
Disclosure: Long APRI.